Marlon Ilagan, MD
Gastroenterology · Orlando, FLNPI 1588716492
Payments from drug & device makers
Across 535 payments — averaging $819.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$373K
- E.r. Squibb & Sons, L.L.C.$21K
- Gilead$15K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- Pfizer$5K
- AbbVie$5K
- plus $5K from 26 others
What the payments were for
- Consulting fees$3,6198%
- Speaking & faculty fees$35,35275%
- Travel & lodging$1780%
- Food & beverage$8,01717%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 98 | $373,443 |
| E.r. Squibb & Sons, L.L.C. | 14 | $21,127 |
| Gilead | 21 | $15,449 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $13,434 |
| Pfizer(2 entities) | 24 | $5,168 |
| AbbVie(2 entities) | 189 | $4,714 |
| Bristol Myers Squibb | 10 | $1,880 |
| Johnson & Johnson | 60 | $1,016 |
| Sanofi | 14 | $382 |
| Madrigal Pharmaceuticals | 14 | $303 |
| Janssen Scientific Affairs, LLC | 3 | $290 |
| Regeneron Healthcare Solutions, Inc. | 10 | $266 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $213 |
| Ipsen Biopharmaceuticals, Inc | 6 | $128 |
| Medical Device Business Services, Inc. | 1 | $117 |
| Lilly USA, LLC | 1 | $113 |
| QOL Medical, LLC | 3 | $94 |
| Intercept Pharmaceuticals, Inc. | 4 | $65 |
| Novo Nordisk | 3 | $53 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Olympus America Inc. | 3 | $45 |
| Romark Laboratories, LC | 2 | $43 |
| Amgen | 2 | $39 |
| Celltrion USA Inc. | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Medtronic | 1 | $17 |
| Enterra Medical, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $14 |
| Covidien LP | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$438,599 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 19 | $174,837 |
| CreonLipase/Protease/Amylase | 39 | $161,651 |
| LinzessLinaclotide | 99 | $117,012 |
| ZenpepLipase/Protease/Amylase | 11 | $51,145 |
| XifaxanRifaximin | 24 | $48,292 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $25,995 |
| MotegrityPrucalopride Succinate | 20 | $25,992 |
| MovantikNaloxegol Oxalate | 45 | $24,728 |
| Mesalamine | 15 | $9,781 |
| Pantoprazole Sodium | 716 | $8,306 |
| Colesevelam Hcl | 48 | $7,388 |
| Ursodiol | 32 | $6,327 |
| Dexlansoprazole DrDexlansoprazole | 14 | $6,165 |
| Lubiprostone | 50 | $4,698 |
| Alosetron Hcl | 27 | $4,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $4,714 | $278,663138 claims |
| QOL Medical, LLCSucraid | $94 | $174,83719 claims |
| Aimmune Therapeutics, Inc.Zenpep | $51 | $51,14511 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $213 | $48,29224 claims |
| GileadDescovy | $15,449 | $25,99512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $13,434 | $25,99220 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $19 | $2,71216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Orlando
- Henry LevineOrlando$3.4M
- Samuel GidayOrlando$2.1M
- Jennifer Seminerio-DiehlOrlando$1.7M
- Huy TranOrlando$1.2M
- Jason KorenblitOrlando$666K
- Saurabh AgrawalOrlando$584K
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.